Advanced therapies, Cell therapy, Regenerative medicine, Manufacturing, CMO, Cell therapy medicinal products, HC016, Acute lung injury, Acute spinal cord injury, Medical devices, Dermo-cosmetics, Wound healing, Ulcers, Complex wounds, Chronic wounds, Skin care, Reoxcare, Histoessence, Wharton Gel Complex
Biopharmaceutical company created in 2004 dedicated to developing, manufacturing and marketing advanced therapy drugs, and healthcare and dermo-cosmetic products in the field of regenerative medicine.
It has facilities that include a GMP manufacturing unit for cell therapy drugs, and a 2000 m2 fully equipped manufacturing plant for healthcare and dermo-cosmetic products in the Bilbao area.
Its products are distinguished by their common therapeutic approach focused on protecting and regenerating tissues damaged by oxidative and inflammatory environments, and are backed by strong intellectual property protection with more than 50 patents.
In addition to ongoing clinical trials with the cell therapy drug HC016 for indications of acute respiratory distress (including patients with COVID-19 infection) and acute spinal cord injury, Histocell produces and markets a line of medical devices Reoxcare for healing wounds, and various products and active ingredients for dermo-cosmetics within the Histoessence line.
DESCRIPTION
Biopharmaceutical company created in 2004 dedicated to developing, manufacturing and marketing advanced therapy drugs, and healthcare and dermo-cosmetic products in the field of regenerative medicine.
It has facilities that include a GMP manufacturing unit for cell therapy drugs, and a 2000 m2 fully equipped manufacturing plant for healthcare and dermo-cosmetic products in the Bilbao area.
Its products are distinguished by their common therapeutic approach focused on protecting and regenerating tissues damaged by oxidative and inflammatory environments, and are backed by strong intellectual property protection with more than 50 patents.
In addition to ongoing clinical trials with the cell therapy drug HC016 for indications of acute respiratory distress (including patients with COVID-19 infection) and acute spinal cord injury, Histocell produces and markets a line of medical devices Reoxcare for healing wounds, and various products and active ingredients for dermo-cosmetics within the Histoessence line.
Keywords
Advanced therapies, Cell therapy, Regenerative medicine, Manufacturing, CMO, Cell therapy medicinal products, HC016, Acute lung injury, Acute spinal cord injury, Medical devices, Dermo-cosmetics, Wound healing, Ulcers, Complex wounds, Chronic wounds, Skin care, Reoxcare, Histoessence, Wharton Gel Complex
